PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Vorinostat

Drugs in development · updated 30 October 2026

Vorinostat: clinical trials and development status

Other names and codes: Zolinza

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 Vorinostat is in 28 active clinical trials (recruiting or ongoing, phases I–III) for 48 diseases. The most advanced phase is II–III.

28Active trials
II–IIIMost advanced phase
48Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Vorinostat and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 48 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Precursor lymphoblastic lymphoma/leukemiaII–III3NCT03117751
LeukemiaII–III1NCT03117751
LymphomaII–III1NCT03117751
Myelodysplastic SyndromesII4NCT01522976
Acute myeloid leukemiaI–II3NCT00392353
NeuroblastomaII3NCT02559778
Breast neoplasmII2NCT00616967
Chronic myelomonocytic leukemiaII2NCT01522976
Diffuse large B-cell lymphomaI–II2NCT03842696
Follicular lymphomaI–II2NCT03842696
Refractory anemia with excess of blastsII2NCT01522976
Accelerated phase chronic myelogenous leukemiaI–II1NCT03842696
Acute erythroid leukemiaI–II1NCT00392353
Acute megakaryoblastic leukemiaI–II1NCT00392353
Blast CrisisI–II1NCT03842696
Breast ductal carcinomaII1NCT00616967
Breast lobular carcinomaII1NCT00616967
Chronic phase chronic myelogenous leukemiaI–II1NCT03842696
Crohn's diseaseI–II1NCT03167437
GATA2 deficiencyII1NCT01522976
Graft-versus-host diseaseI–II1NCT03842696
Hematologic DiseasesI–II1NCT03842696
Lung neoplasmI–II1NCT02638090
Mantle cell lymphomaI–II1NCT03842696
Multiple myelomaI–II1NCT01297764
Non-Hodgkin lymphomaI–II1NCT03842696
Non-small-cell lung carcinomaI–II1NCT02638090
Prostatic NeoplasmsII1NCT06145633
Refractory anemiaI–II1NCT00392353
Uveal melanomaII1NCT01587352

Everything on Vorinostat

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch